All AbMole products are for research use only, cannot be used for human consumption.
FKBP12 PROTAC dTAG-13 (dTAG-13), a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12F36V with expression of FKBP12F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-13 effectively engages FKBP12F36V and CRBN, thereby selectively degrading FKBP12F36V.
| Cell Experiment | |
|---|---|
| Cell lines | ND7/23 cells |
| Preparation method | ND7/23 cells were transfected in 10 cm plates with NaV1.8-dTAG and then treated with either DMSO or dTAG-13 for 24 hours. |
| Concentrations | 0.1 - 1000 nM |
| Incubation time | 24 hours |
| Animal Experiment | |
|---|---|
| Animal models | WT C57BL/6J mice |
| Formulation | Solutol: DMSO: Saline [20:5:75] [v:v:v] |
| Dosages | 1 mg/kg |
| Administration | dTAG-13 delivered IV in an IV formulation (DMSO: PEG400: Water [10:50:40] [v: v: v]) at 1 mg/kg, dTAG-13 delivered IP in Formulation (Solutol: DMSO: Saline [20:5:75] [v:v:v]) at a single dose level |
| Molecular Weight | 1049.17 |
| Formula | C57H68N4O15 |
| CAS Number | 2064175-41-1 |
| Form | Solid |
| Solubility (25°C) | DMSO ≥ 100 mg/mL (ultrasonic) |
| Storage | Powder -20°C |
| Related PROTAC Products |
|---|
| CR8
CR8 is a potent and selective inhibitor of cyclin dependent kinase (CDK1, 2, 5, 7, and 9). |
| ARV-393
ARV-393 is an orally active PROTAC degrader targeting BCL6 for studies related to diffuse large B-cell lymphoma. ARV-393 utilizes the ubiquitin-proteasome system to target the degradation of BCL6. |
| ARV-766
ARV-766 is an orally active and potent proteolysis targeting chimera (PROTAC) protein degrader. ARV-766 degrades wild-type androgen receptor (AR) but also relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations. ARV-766 has the potential to be first- and best-in class PROTAC AR degrader in mCRPC. |
| Indisulam
Indisulam is a carbonic anhydrase inibitor and antitumor CDK inhibitor. Indisulam targets the G1 phase of the cell cycle by depleting cyclin E. inducing p53 and p21, and inhibiting CDK2, causing a blockade in the G1/S transition. |
| dBET6
dBET6 is a highly potent, selective and cell-permeable PROTAC connected by ligands for Cereblon and BET, with an IC50 of 14 nM, and has antitumor activity. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
